19406-00-9

Usage

Uses

Used in Chemical Synthesis:
3-Furancarboxylic Acid, Tetrahydro-2-oxo-, Methyl Ester is used as a chemical intermediate for the synthesis of various compounds in the chemical industry. Its unique molecular structure allows it to be a versatile building block in the creation of different chemical products.
Used in Research Applications:
In the field of scientific research, 3-Furancarboxylic Acid, Tetrahydro-2-oxo-, Methyl Ester is used as a reagent or a model compound to study the properties and reactions of furan-based compounds. This helps researchers understand the behavior of similar compounds and their potential applications in various fields.
Used in Pharmaceutical Development:
3-Furancarboxylic Acid, Tetrahydro-2-oxo-, Methyl Ester is used as a starting material in the development of pharmaceutical drugs. Its unique structure may contribute to the creation of new drug candidates with potential therapeutic applications.
Used in Material Science:
In material science, 3-Furancarboxylic Acid, Tetrahydro-2-oxo-, Methyl Ester is used as a component in the development of new materials with specific properties. Its incorporation into polymers or other materials can lead to the creation of materials with improved characteristics, such as enhanced stability or reactivity.

InChI:InChI=1/C6H8O4/c1-9-5(7)4-2-3-10-6(4)8/h4H,2-3H2,1H3

Upstream product

• 96-48-0 4-butanolide 
• 616-38-6 carbonic acid dimethyl ester 
• 6914-71-2 dimethyl 1,1-cyclopropanedicarboxylate 
• 67-56-1 methanol 
• 108-59-8 malonic acid dimethyl ester 
• 598-10-7 cyclopropane-1,1-dicarboxylic acid 
• 74-88-4 methyl iodide 
• 4525-33-1 dimethyl dicarbonate 
• 107-31-3 Methyl formate 

Downstream Products

• 63731-11-3 2-oxo-2,5-dihydro-furan-3-carboxylic acid methyl ester 
• 186510-03-2 3-Hydroxy-2-oxo-tetrahydro-furan-3-carboxylic acid methyl ester 
• 1007208-63-0 [3-[4-[2-[bis[(4-methoxyphenyl)methyl]amino]pyrimidin-5-yl]-2-morpholin-4-yl-5,6-dihydropyrrolo[2,3-d]pyrimidin-7-yl]phenyl]-(4-methylpiperazin-1-yl)methanone 
• 1007208-13-0 4-[4-[2-[bis[(4-methoxyphenyl)methyl]amino]pyrimidin-5-yl]-2-morpholino-5,6-dihydropyrrolo[2,3-d]pyrimidin-7-yl]benzaldehyde 
• 1007209-85-9 5-[2-morpholino-7-[4-(morpholinomethyl)phenyl]-5,6-dihydropyrrolo[2,3-d]pyrimidin-4-yl]pyrimidin-2-amine 
• 1007208-40-3 [4-[4-(2-aminopyrimidin-5-yl)-2-morpholino-5,6-dihydropyrrolo[2,3-d]pyrimidin-7-yl]phenyl]-(4-methylpiperazin-1-yl)methanone 
• 1007210-13-0 [4-(4-{2-[bis-(4-methoxy-benzyl)-amino]-pyrimidin-5-yl}-2-morpholin-4-yl-5,6-dihydro-pyrrolo[2,3-d]pyrimidin-7-yl)-phenyl]-(4-methyl-piperazin-1-yl)-methanone 
• 1007208-67-4 5-(2-morpholino-7-phenyl-5,6-dihydropyrrolo[2,3-d]pyrimidin-4-yl)pyrimidin-2-amine 

Relevant academic research and scientific papers

BICYCLIC HETEROARENES AND METHODS OF THEIR USE

Disclosed are compounds useful in the treatment of neurological disorders. The compounds described herein, alone or in combination with other pharmaceutically active agents, can be used for treating or preventing neurological diseases.

A Unified Strategy for the Synthesis of Difluoromethyl- And Vinylfluoride-Containing Scaffolds

Here, we report a general method for the synthesis of quaternary and tertiary difluoromethylated compounds and their vinylfluoride analogues. The strategy, which relies on a two-step sequence featuring a C-selective electrophilic difluoromethylation and either a palladium-catalyzed decarboxylative protonation or a Krapcho decarboxylation, is practical, scalable, and high yielding. Considering the generality of the method and the attractive properties offered by the difluoromethyl group, this approach provides a valuable tool for late-stage functionalization and drug development.

Pyrrolidines and Piperidines by Ligand-Enabled Aza-Heck Cyclizations and Cascades of N-(Pentafluorobenzoyloxy)carbamates

Ligand-enabled aza-Heck cyclizations and cascades of N-(pentafluorobenzoyloxy)carbamates are described. These studies encompass the first examples of efficient non-biased 6-exo aza-Heck cyclizations. The methodology provides direct and flexible access to carbamate protected pyrrolidines and piperidines.

Enantioselective phase-transfer catalytic α-benzylation and α-allylation of α-tert-butoxycarbonyllactones

A new enantioselective α-benzylation and α-allylation of α-tert-butoxycarbonyllactones was devloped. α-Benzylation and α-allylation of α-tert-butoxycarbonylbutyrolactone and α-tert-butoxycarbonylvalerolactone under phase-transfer catalytic conditions (50% cesium hydroxide, toluene, -60 °C) in the presence of (S,S)-3,4,5-trifluorophenyl-NAS bromide (1 mol%) afforded the corresponding α-substituted α-tert-butoxycarbonyllactones in very high chemical yields (up to 99%) and optical yields (up to 99% ee). The synthetic potential of this method has been successfully demonstrated by the asymmetric synthesis of unnatural α-quaternary homoserines, 3-alkyl-3-carboxypyrrolidine and 3-alkyl-3-carboxypiperidine. Copyright

Lead optimization of a dihydropyrrolopyrimidine inhibitor against phosphoinositide 3-kinase (PI3K) to improve the phenol glucuronic acid conjugation

Our lead compound for a phosphoinositide 3-kinase (PI3K) inhibitor (1) was metabolically unstable because of rapid glucuronidation of the phenol moiety. Based on structure-activity relationship (SAR) information and a FlexSIS docking simulation score, aminopyrimidine was identified as a bioisostere of phenol. An X-ray structure study revealed a hydrogen bonding pattern of aminopyrimidine derivatives. Finally, aminopyrimidine derivatives 33 showed strong tumor growth inhibition against a KPL-4 breast cancer xenograft model in vivo.

HETEROCYCLIC AMIDES AS ROCK INHIBITORS

The present invention relates to new kinase inhibitors of formula (I), more specifically ROCK inhibitors, compositions, in particular pharmaceuticals, comprising such inhibitors, and to uses of such inhibitors in the treatment and prophylaxis of disease. In particular, the present invention relates to new ROCK inhibitors, compositions, in particular pharmaceuticals, comprising such inhibitors, and to uses of such inhibitors in the treatment and prophylaxis of disease. In addition, the invention relates to methods of treatment and use of said compounds in the manufacture of a medicament for the application to a number of therapeutic indications including sexual dysfunction, inflammatory diseases, ophthalmic diseases and Respiratory diseases.

PYRIMIDINE DERIVATIVE AS PI3K INHIBITOR AND USE THEREOF

A drug is provided that is useful as a preventive or therapeutic for cancer as a result of having superior PI3K inhibitory effects as well as superior stability in the body and water-solubility. A compound, or pharmaceutically acceptable salt thereof, rep

SYNTHESIS OF TETRAHYDRO-1,2-OXAZINES BY THE CYCLOADDITION OF NITRONES WITH CYCLOPROPANES

One aspect of the present invention relates to a method of preparing tetrahydro-1,2- oxazines comprising the step of combining a nitrone and a cyclopropane in the presence of a Lewis acid. Another aspect of the present invention relates to a method of preparing a tetrahydro-1,2-oxazine, comprising the step of combining an aldehyde and a hydroxylamine in the presence of a Lewis acid to generate a nitrone in situ, then admixing a cyclopropane. Another aspect of the present invention relates to converting a tetrahydro-l,2-oxazine to a pyrrolidine comprising the step of admixing a tetrahydro-1,2-oxazine and a reducing agent.

NOVEL PURINE- OR PYRROLOL[2,3-d]PYRIMIDINE-2-CARBONITILES FOR TREATING DISEASES ASSOCIATED WITH CYSTEINE PROTEASE ACTIVITY

The present invention therefore provides a compound of formula (I) and compositions for treating diseases associated with cysteine protease activity. The compounds are reversible inhibitors of cysteine proteases S, K, F, L and B. Of particular interest ar

-Alkoxystannyl ethers in organic synthesis: Synthesis of functionalised γ-butyrolactones

Ozonolysis of a variety of (tetraydrofuran-2-yl)tri-n-butylstannanes affords the corresponding γ-butyrolactones in good to excellent yields. This reaction is tolerant to a range of other functional groups and provides access to substituted γ-butyrolactone